Abdera Therapeutics

company

About

Abdera is an oncology company developing targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers.

  • 1 - 10

Details

Last Funding Type
Series A
Industries
Biotechnology,Health Care,Health Diagnostics,Life Science
Founded date
Jan 1, 2021
Number Of Employee
1 - 10
Operating Status
Active

Abdera is an oncology company developing targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers. Its targeted radiotherapies utilize purpose-built vectors to specifically target high-energy radio-isotopes to tumors and metastatic cancer lesions. This new class of drugs holds tremendous untapped therapeutic and commercial potential, and has generated over $10B in recent M&A, financings, and product launches – and are expected to comprise 70% of the $30B nuclear medicine market by 2030.

It was launched by adMare BioInnovations, Canada’s global life sciences venture, in partnership with industry leaders AbCellera, and some of the country’s most successful scientist entrepreneurs.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
Abdera Therapeutics has raised a total of — in funding over 2 rounds. Their latest funding was raised on Apr 20, 2023 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Apr 20, 2023 Series A 1 Versant Ventures Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Abdera Therapeutics is funded by 1 investors. Versant Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Versant Ventures Yes Series A